keyword
MENU ▼
Read by QxMD icon Read
search

Cancer related anemia

keyword
https://www.readbyqxmd.com/read/27914067/5q-syndrome-like-features-as-the-first-manifestation-of-myelodysplastic-syndrome-in-a-patient-with-an-unbalanced-whole-arm-translocation-der-5-19-p10-q10
#1
Hiroshi Ureshino, Haruna Kizuka, Kana Kusaba, Haruhiko Sano, Atsujiro Nishioka, Takero Shindo, Yasushi Kubota, Toshihiko Ando, Kensuke Kojima, Shinya Kimura
Derivative (5;19)(p10;q10) [der(5;19)(p10;q10)] is a rare chromosomal abnormality in myelodysplastic syndrome (MDS), and is genetically similar to deletion 5q [del(5q)]. However, MDS with der(5;19)(p10;q10) and 5q- syndrome are generally characterized as distinct subtypes. Here, we report a case of a patient with 5q- syndrome-like features as the first manifestation of MDS with der(5; 19)(p10;q10). A 59-year-old woman was admitted to our hospital for anemia without leukopenia and thrombocytopenia. She had received chemotherapy comprising carboplatin and docetaxel for endometrial cancer eight years before...
December 2, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27913001/cancer-related-fatigue-persistent-pervasive-and-problematic
#2
REVIEW
Lynn H Gerber
Cancer-related fatigue (CRF) is commonly reported by patients with cancer before, during, and after treatment. It is a persistent sense of tiredness that interferes with function, is distressing, and requires monitoring and, possibly, treatment. Fatigue assessment requires objective measures and self-reports, such as Functional Assessment of Cancer Therapy-Fatigue. Significant contributors to CRF include anemia, pain, insomnia, depressive symptoms, and elevated BMI. Elevated inflammatory cytokines, diabetes mellitus, cortisol, and cellular dysregulation have been associated with CRF...
February 2017: Physical Medicine and Rehabilitation Clinics of North America
https://www.readbyqxmd.com/read/27906684/phase-i-study-of-the-gamma-secretase-inhibitor-pf-03084014-in-combination-with-docetaxel-in-patients-with-advanced-triple-negative-breast-cancer
#3
Marzia A Locatelli, Philippe Aftimos, E Claire Dees, Patricia M LoRusso, Mark D Pegram, Ahmad Awada, Bo Huang, Rossano Cesari, Yuqiu Jiang, M Naveed Shaik, Kenneth A Kern, Giuseppe Curigliano
BACKGROUND: The NOTCH signaling pathway may be involved in the survival of stem cell-like tumor-initiating cells and contribute to tumor growth. In this phase Ib, open-label, multicenter study (NCT01876251), we evaluated PF-03084014, a selective gamma-secretase inhibitor in patients with advanced triple-negative breast cancer. METHODS: The dose-finding part was based on a 2×3 matrix design using the modified toxicity probability interval method. Oral PF-03084014 was administered twice daily continuously in combination with intravenous docetaxel given on day 1 of each 21-day cycle...
November 30, 2016: Oncotarget
https://www.readbyqxmd.com/read/27906669/hemoglobin-level-trajectories-in-the-early-treatment-period-are-related-with-survival-outcomes-in-patients-with-breast-cancer
#4
Chia-Lin Lee, Chun-Hao Tsai, Dah-Cherng Yeh, Chi-Shy Lin, Yu-Fen Li, Huey-En Tzeng
Hemoglobin (Hb) levels are reportedly related with treatment outcomes and survival in patients of breast cancer. However, the long-term change in Hb levels after treatment and the effects of Hb on survival remain unknown. This retrospective cohort study enrolled 1931 breast cancer patients with pathological stage I-IV between 1/1/2003 and 12/31/2013. Latent class modeling was used to identify trajectories in monthly Hb levels over time. The primary endpoint was 10-year cancer-related death. We identified 5 distinct Hb trajectories: persistent anemia (5...
November 29, 2016: Oncotarget
https://www.readbyqxmd.com/read/27904656/the-berlin-treatment-algorithm-recommendations-for-tailored-innovative-therapeutic-strategies-for-multiple-sclerosis-related-fatigue
#5
REVIEW
Christian Veauthier, Helge Hasselmann, Stefan M Gold, Friedemann Paul
More than 80% of multiple sclerosis (MS) patients suffer from fatigue. Despite this, there are few therapeutic options and evidence-based pharmacological treatments are lacking. The associated societal burden is substantial (MS fatigue is a major reason for part-time employment or early retirement), and at least one out of four MS patients view fatigue as the most burdensome symptom of their disease. The mechanisms underlying MS-related fatigue are poorly understood, and objective criteria for distinguishing and evaluating levels of fatigue and tiredness have not yet been developed...
2016: EPMA Journal
https://www.readbyqxmd.com/read/27902478/a-retrospective-clinical-study-of-comparing-paclitaxel-plus-s-1-versus-paclitaxel-plus-cisplatin-as-the-first-line-treatment-for-patients-with-advanced-esophageal-squamous-cell-carcinoma
#6
Hai-Ying Wang, Zhi-Hua Yao, Hong Tang, Yan Zhao, Shui-Ling Jin, Wen-Ping Zhou, Shu-Na Yao, Shu-Jun Yang, Yan-Yan Liu, Su-Xia Luo
BACKGROUND: In advanced esophageal squamous cell carcinoma (ESCC), paclitaxel plus cisplatin are considered as active and tolerable. The current clinical study was conducted to retrospectively compare the efficacy and safety of first-line paclitaxel/S-1(PS) and paclitaxel/cisplatin(TP) regimens in advanced ESCC. RESULTS: The overall response rate of PS was slightly, but not significantly, higher (25 patients, 46%) than that of TP (23 patients, 39%, P = 0.432). Median overall survival (OS) was similar for PS and TP (11...
November 25, 2016: Oncotarget
https://www.readbyqxmd.com/read/27896324/the-relationship-between-anemia-and-recurrence-of-ischemic-stroke-in-patients-with-trousseau-s-syndrome-a-retrospective-cross-sectional-study
#7
Mehmet Yigit, Ozgur Sogut, Eda Yigit, Kenan Ahmet Turkdogan, Onur Kaplan, Ali Dur, Ertan Sonmez, Bulut Demirel
OBJECTIVES: The relationship between cancer and thrombosis was first recognized by the French internist Armand Trousseau in 1865. Trousseau's syndrome is a spectrum of symptoms that result from recurrent thromboembolism associated with cancer or malignancy-related hypercoagulability. In this study, we investigated whether demographics, clinical features, or laboratory findings were able to predict recurrent stroke episodes in patients with Trousseau's syndrome. METHODS: In total, 178 adult patients were enrolled in this retrospective cross-sectional study...
June 2016: Turkish Journal of Emergency Medicine
https://www.readbyqxmd.com/read/27872759/impact-of-moderate-intensity-aerobic-exercise-on-chemotherapy-induced-anemia-in-elderly-women-with-breast-cancer-a-randomized-controlled-clinical-trial
#8
Heba M Mohamady, Hany F Elsisi, Yasser M Aneis
Exercises are often recommended for patients suffering from anemia to improve physical conditioning and hematologic parameters. Hence, the present study aimed to investigate the impact of moderate intensity aerobic exercise on chemotherapy-induced anemia. Thirty elderly women with breast cancer underwent chemotherapy and were randomly assigned into two equal groups; Group A received aerobic exercise for 25-40 min at 50-70% of the maximum heart rate, 3 times/week for 12 weeks in addition to usual daily living activities, medication and nutritional support...
January 2017: Journal of Advanced Research
https://www.readbyqxmd.com/read/27870581/everolimus-in-patients-with-advanced-follicular-derived-thyroid-cancer-results-of-a-phase-ii-clinical-trial
#9
T C Schneider, D de Wit, T P Links, N P van Erp, J J M van der Hoeven, H Gelderblom, C F M Roozen, M Bos, W E Corver, T van Wezel, J W A Smit, H Morreau, H J Guchelaar, E Kapiteijn
BACKGROUND: mTOR upregulation has been reported to be involved in the pathogenesis of thyroid tumors and treatment with the mTOR inhibitor everolimus has shown promising results in endocrine tumors. We conducted a prospective phase II clinical trial to determine the efficacy and safety of everolimus in patients with advanced differentiated thyroid cancer. PATIENTS AND METHODS: Twenty-eight patients with progressive metastatic or locally advanced radioactive refractory differentiated thyroid cancer and 7 patients with anaplastic thyroid cancer were included and received everolimus 10mg orally once daily...
November 21, 2016: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/27868334/consensus-on-the-standardization-of-terminology-in-thrombotic-thrombocytopenic-purpura-and-related-thrombotic-microangiopathies
#10
M Scully, S Cataland, P Coppo, J de la Rubia, K D Friedman, J Kremer Hovinga, B Lämmle, M Matsumoto, K Pavenski, E Sadler, R Sarode, H Wu
BACKGROUND: Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are two important acute conditions to diagnose. Thrombotic Microangiopathy is a broad pathophysiological process that leads to microangiopathic hemolytic anemia, thrombocytopenia and involves capillary and small vessel platelet aggregates. The most common cause being disseminated intravascular coagulation (DIC), which may be differentiated by abnormal coagulation. Clinically, a number of conditions present with microangiopathic hemolytic anemia and thrombocytopenia (MAHAT), including cancer, infection, transplantation, drugs, autoimmune disease and pre-eclampsia and HELLP (Hemolysis, Elevated Liver enzymes, Low Platelet count) syndrome in pregnancy...
November 21, 2016: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/27863761/iron-deficiency-in-cancer-patients
#11
Flávio Augusto Naoum
Anemia is a frequent complication in cancer patients, both at diagnosis and during treatment, with a multifactorial etiology in most cases. Iron deficiency is among the most common causes of anemia in this setting and can develop in nearly half of patients with solid tumors and hematologic malignancies. Surprisingly, this fact is usually neglected by the attending physician in a way that proper and prompt investigation of the iron status is either not performed or postponed. In cancer patients, functional iron deficiency is the predominant mechanism, in which iron availability is reduced due to disease or the therapy-related inflammatory process...
October 2016: Revista Brasileira de Hematologia e Hemoterapia
https://www.readbyqxmd.com/read/27853997/a-phase-i-trial-investigating-pulsatile-erlotinib-in-combination-with-gemcitabine-and-oxaliplatin-in-advanced-biliary-tract-cancers
#12
Laura W Goff, Dana B Cardin, Jennifer G Whisenant, Liping Du, Tatsuki Koyama, Kimberly B Dahlman, Safia N Salaria, Ruth T Young, Kristen K Ciombor, Jill Gilbert, Stephen James Smith, Emily Chan, Jordan Berlin
Advanced biliary tract cancers (ABTC) are among the deadliest malignancies with limited treatment options after progression on standard-of-care chemotherapy, which includes gemcitabine (GEM) and oxaliplatin (OX). The epidermal growth factor receptor inhibitor erlotinib has been explored in ABTC with modest efficacy. Erlotinib given continuously may antagonize the action of chemotherapy against cycling tumor cells, but pulsatile dosing of erlotinib with chemotherapy may improve efficacy. The purpose of this study was to assess the safety of pulsatile erlotinib with GEMOX...
November 16, 2016: Investigational New Drugs
https://www.readbyqxmd.com/read/27827319/the-salivary-microbiome-and-oral-cancer-risk-a-pilot-study-in-fanconi-anemia
#13
C P Furquim, G M S Soares, L L Ribeiro, M A Azcarate-Peril, N Butz, J Roach, K Moss, C Bonfim, C C Torres-Pereira, F R F Teles
Fanconi anemia (FA) is a rare genetic disease characterized by chromosomal instability and impaired DNA damage repair. FA patients develop oral squamous cell carcinoma (OSCC) earlier and more frequently than the general population, especially after hematopoietic stem cell transplantation (HSCT). Although evidence of an etiological role of the local microbiome and carcinogenesis has been mounting, no information exists regarding the oral microbiome of FA patients. The aim of this study was to explore the salivary microbiome of 61 FA patients regarding their oral health status and OSCC risk factors...
November 8, 2016: Journal of Dental Research
https://www.readbyqxmd.com/read/27825651/sequential-four-drug-chemotherapy-and-intensity-modulated-radiotherapy-for-larynx-preservation-in-resectable-advanced-larynx-and-hypopharynx-cancer-a-pilot-study
#14
Xuan Su, Caiyun He, Tao Tang, Weichao Chen, Zhaoqu Li, Yong Chen, Ankui Yang
OBJECTIVE: The value of additional use of cetuximab with the classical cisplatin, docetaxel and 5-fluorouracil regimen in larynx preservation remains unknown. This study was designed to resolve this issue and appraise its toxicity. MATERIALS AND METHODS: Thirteen untreated patients with stage III-IV larynx or hypopharynx squamous cell carcinoma were recruited and received two cycles of C+TPF regimen (cetuximab plus docetaxel, cisplatinand and 5-fluorouracil), followed by one more cycle of C+TPF and intensity-modulated radiotherapy (70Gy)...
September 28, 2016: American Journal of Otolaryngology
https://www.readbyqxmd.com/read/27825568/osteoarticular-manifestations-of-celiac-disease-and-non-celiac-gluten-hypersensitivity
#15
Stéphanie Dos Santos, Frédéric Lioté
Celiac disease is a chronic inflammatory autoimmune enteropathy based disorder that is triggered by the ingestion of gluten in genetically susceptible individuals. The global prevalence of 1% to 2% represents only the tip of the iceberg. The diagnosis is confirmed by positive specific antibody, anti-transglutaminase or anti-endomysium, specific lesions of the small intestine and a response to strict gluten-free diet. The diagnosis is difficult and often delayed because the clinical variability is very large, ranging from digestive clinical presentation "classic" to "atypical" symptoms, often extra-intestinal, that are sometimes attributed to a concomitant disease or a complication...
November 4, 2016: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/27822072/efficacy-and-toxicities-of-adding-molecular-targeted-agents-to-first-line-chemotherapy-in-the-treatment-of-advanced-biliary-tract-cancer-a-systematic-review-and-meta-analysis
#16
Sheng Zhao, Yanping Miao, Ruijun Wang, Haidong Guo, Feng Jin, Xiuling Guo, Tianyou Luo
PURPOSE: The purpose of this study was to assess the efficacy and toxicities of adding molecular targeted agents (MTAs) to first-line chemotherapy in the treatment of advanced biliary tract cancer (BTC). METHODS: An extensive search for relevant clinical trials was conducted in electronic databases (PubMed, Web of Science, and Cochrane) and abstracts presented at meetings. Prospective randomized controlled trials (RCTs) reporting the efficacy and toxicity of chemotherapies with or without MTAs in advanced BTC were selected...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27815358/phase-i-study-of-gdc-0425-a-checkpoint-kinase-1-inhibitor-in-combination-with-gemcitabine-in-patients-with-refractory-solid-tumors
#17
Jeffrey R Infante, Antoine Hollebecque, Sophie Postel-Vinay, Todd M Bauer, Elizabeth Blackwood, Marie Evangelista, Sami Mahrus, Franklin Peale, Xuyang Lu, Srikumar Sahasranaman, Rui Zhu, Yuan Chen, Xiao Ding, Elaine Murray, Jennifer Schutzman, Jennifer O Lauchle, Jean-Charles Soria, Patricia M LoRusso
PURPOSE: Chk1 inhibition potentiates DNA-damaging chemotherapy by overriding cell cycle arrest and genome repair. This Phase I study evaluated the Chk1 inhibitor GDC-0425 given in combination with gemcitabine to patients with advanced solid tumors. EXPERIMENTAL DESIGN: Patients received GDC-0425 alone for a 1-week lead-in followed by 21-day cycles of gemcitabine plus GDC-0425. Gemcitabine was initially administered at 750 mg/m2 (Arm A), then increased to 1000 mg/m2 (Arm B), on Days 1 and 8 in a 3+3+3 dose escalation to establish maximum tolerated dose (MTD)...
November 4, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27813022/a-case-of-retrograde-intussusception-at-roux-en-y-anastomosis-10%C3%A2-years-after-total-gastrectomy-review-of-the-literature
#18
Yuhei Kitasato, Ryuta Midorikawa, Yoshihiro Uchino, Shuko Saku, Taizan Minami, Takahisa Shirahama, Kazumitsu Kiyomatsu, Koji Okuda, Yoshito Akagi, Hiroyuki Tanaka
A 63-year-old man, who had undergone total gastrectomy and Roux-en-Y reconstruction for gastric cancer 10 years previously, was admitted to our hospital with complaints of abdominal pain, palpable abdominal tumor, and hematemesis. On admission, the abdominal tenderness was improving and no abdominal tumor was palpable. Mild inflammatory changes and anemia were noted on blood examination. Abdominal computed tomography revealed a tumor with a layered structure in the left abdomen. The patient was diagnosed with intestinal obstruction secondary to intussusception, and surgery was performed...
December 2016: Surgical Case Reports
https://www.readbyqxmd.com/read/27802181/carboplatin-induced-hematotoxicity-among-patients-with-non-small-cell-lung-cancer-analysis-on-clinical-adverse-events-and-drug-gene-interactions
#19
Yi-Ju Cheng, Ran Wu, Ming-Liang Cheng, Juan Du, Xi-Wei Hu, Lei Yu, Xue-Ke Zhao, Yu-Mei Yao, Qi-Zhong Long, Li-Li Zhu, Juan-Juan Zhu, Ni-Wen Huang, Hua-Juan Liu, Ya-Xin Hu, Fang Wan
In order to clarify the risk of hematotoxicity of carboplatin, we inspected 19901 case reports of non-small cell lung cancer patients that were submitted to the FDA Adverse Event Reporting System (FAERS) between January 2004 and December 2015. These comprised 3907 cases which were treated with carboplatin and 15994 cases which were treated with other therapies in the absence of carboplatin. By comparison, carboplatin cases were significantly more likely to report anemia (OR = 2.27, 95% CI 1.85-2.78, P = 5.04×10-15), neutropenia (OR = 2...
October 27, 2016: Oncotarget
https://www.readbyqxmd.com/read/27797249/impact-of-the-copper-transporter-protein-1-ctr1-polymorphism-on-adverse-events-among-advanced-nonsmall-cell-lung-cancer-patients-treated-with-a-carboplatin-gemcitabine-regimen
#20
Siriluk Kumpiro, Virote Sriuranpong, Nutthada Areepium
BACKGROUND: Platinum-based regimens are effective treatments for advanced non-small cell lung cancer (NSCLC), but the five-year survival rate is still less than 20%. One possible factor appears to be resistance involving polymorphisms in the CTR1 gene which plays an importance role in accumulation of platinum in the cytoplasm. PURPOSE: To establish both prevalence of CTR1 polymorphism and its impact on treatment related toxicity in Thai advanced NSCLC patients. MATERIALS AND METHODS: Thirty-two advanced NSCLC participants received carboplatin and gemcitabine during January to June 2016 at King Chulalongkorn Memorial Hospital (KCMH) were recruited for analysis of the CTR1 rs12686377 genotype...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
keyword
keyword
34939
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"